Aspira Pathlab & Diagnostics Limited (BOM:540788)
India · Delayed Price · Currency is INR 90.05
-1.80 (-1.96%)
At close: Aug 21, 2026
BOM:540788 Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 260.23 | 249.82 | 219.99 | 132.05 | 144.57 | 195.42 | |
Revenue Growth | 15.09% | 13.56% | 66.60% | -8.66% | -26.02% | 28.52% |
Cost of Revenue | 153.06 | 146.33 | 122.9 | 97.88 | 88.63 | 95.62 |
Gross Profit | 107.16 | 103.49 | 97.09 | 34.17 | 55.94 | 99.8 |
Selling, General & Admin | - | - | 2.7 | 3.15 | 5.16 | 2 |
Other Operating Expenses | 96.11 | 88.86 | 58.83 | 42.9 | 34.85 | 34.06 |
Operating Expenses | 111.93 | 104.24 | 76.46 | 61.43 | 55.86 | 52.42 |
Operating Income | -4.77 | -0.75 | 20.63 | -27.26 | 0.08 | 47.38 |
Interest Expense | -3.87 | -3.89 | -3.05 | -3.17 | -3.67 | -3.08 |
Interest & Investment Income | - | - | 3.69 | 3.99 | 2.91 | 0.95 |
Earnings From Equity Investments | 0.48 | - | -0.5 | - | - | - |
Other Non Operating Income (Expenses) | 4.08 | 5.16 | -0.23 | -0.45 | -0.33 | -0.65 |
EBT Excluding Unusual Items | -4.08 | 0.51 | 20.54 | -26.89 | -1.01 | 44.59 |
Gain (Loss) on Sale of Assets | - | - | -0.32 | - | 0.04 | - |
Other Unusual Items | - | - | 0.01 | 0.17 | 0.08 | - |
Pretax Income | -4.08 | 0.51 | 20.23 | -26.72 | -0.89 | 44.59 |
Net Income | -4.08 | 0.51 | 20.23 | -26.72 | -0.89 | 44.59 |
Net Income to Common | -4.08 | 0.51 | 20.23 | -26.72 | -0.89 | 44.59 |
Net Income Growth | - | -97.46% | - | - | - | 222.91% |
Shares Outstanding (Basic) | 10 | 10 | 10 | 10 | 10 | 10 |
Shares Outstanding (Diluted) | 10 | 10 | 10 | 10 | 10 | 10 |
Shares Change | -4.16% | -0.32% | - | - | - | 8.12% |
EPS (Basic) | -0.41 | 0.05 | 1.97 | -2.60 | -0.09 | 4.33 |
EPS (Diluted) | -0.41 | 0.05 | 1.97 | -2.60 | -0.09 | 4.33 |
EPS Growth | - | -97.46% | - | - | - | 198.62% |
Additional Metrics
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Free Cash Flow | - | 7.58 | 14.83 | 7.92 | -1.43 | 14.32 |
Free Cash Flow Per Share | - | 0.74 | 1.44 | 0.77 | -0.14 | 1.39 |
Gross Margin | 41.18% | 41.43% | 44.14% | 25.88% | 38.69% | 51.07% |
Operating Margin | -1.83% | -0.30% | 9.38% | -20.64% | 0.05% | 24.24% |
Profit Margin | -1.57% | 0.21% | 9.19% | -20.24% | -0.61% | 22.82% |
Free Cash Flow Margin | - | 3.03% | 6.74% | 6.00% | -0.99% | 7.33% |
EBITDA | 10.73 | 14.63 | 28.2 | -19.23 | 8.08 | 56.79 |
EBITDA Margin | 4.12% | 5.86% | 12.82% | -14.56% | 5.59% | 29.06% |
D&A For EBITDA | 15.5 | 15.38 | 7.57 | 8.02 | 8.01 | 9.42 |
EBIT | -4.77 | -0.75 | 20.63 | -27.26 | 0.08 | 47.38 |
EBIT Margin | -1.83% | -0.30% | 9.38% | -20.64% | 0.05% | 24.24% |
Revenue as Reported | 264.31 | 254.98 | 223.88 | 136.26 | 147.78 | 196.37 |
Advertising Expenses | - | - | 2.33 | 2.66 | 2.66 | 1.65 |